Literature DB >> 29343556

RASA1/NF1-Mutant Lung Cancer: Racing to the Clinic?

Shunsuke Kitajima1, David A Barbie2.   

Abstract

Although mutation of NF1 has been described in non-small cell lung cancer (NSCLC), co-mutation with RASA1, another Ras-GTPase activating protein (RasGAP), defines a novel genetically defined subclass of NSCLC. RASA1/NF1-mutant cell lines are highly sensitive to MEK inhibitors, warranting clinical evaluation of MAPK inhibition in this subclass of patients. Clin Cancer Res; 24(6); 1243-5. ©2018 AACRSee related article by Hayashi et al., p. 1436. ©2018 American Association for Cancer Research.

Entities:  

Mesh：

Substances：

Year:  2018        PMID： 29343556      PMCID： PMC5856629          DOI： 10.1158/1078-0432.CCR-17-3597

Source DB:  PubMed          Journal:  Clin Cancer Res        ISSN： 1078-0432            Impact factor:   12.531


  5 in total

1.  Dabrafenib plus trametinib in patients with previously untreated BRAFV600E-mutant metastatic non-small-cell lung cancer: an open-label, phase 2 trial.

Authors:  David Planchard; Egbert F Smit; Harry J M Groen; Julien Mazieres; Benjamin Besse; Åslaug Helland; Vanessa Giannone; Anthony M D'Amelio; Pingkuan Zhang; Bijoyesh Mookerjee; Bruce E Johnson
Journal:  Lancet Oncol       Date:  2017-09-11       Impact factor: 41.316

2.  RASA1 and NF1 are Preferentially Co-Mutated and Define A Distinct Genetic Subset of Smoking-Associated Non-Small Cell Lung Carcinomas Sensitive to MEK Inhibition.

Authors:  Takuo Hayashi; Patrice Desmeules; Roger S Smith; Alexander Drilon; Romel Somwar; Marc Ladanyi
Journal:  Clin Cancer Res       Date:  2017-11-10       Impact factor: 12.531

3.  Response to Crizotinib in a Patient With Lung Adenocarcinoma Harboring a MET Splice Site Mutation.

Authors:  Russell W Jenkins; Geoffrey R Oxnard; Sheryl Elkin; E Kelly Sullivan; Jennifer L Carter; David A Barbie
Journal:  Clin Lung Cancer       Date:  2015-02-07       Impact factor: 4.785

Review 4.  Inflammation as a driver and vulnerability of KRAS mediated oncogenesis.

Authors:  Shunsuke Kitajima; Rohit Thummalapalli; David A Barbie
Journal:  Semin Cell Dev Biol       Date:  2016-06-11       Impact factor: 7.727

5.  A randomized phase II study of the MEK1/MEK2 inhibitor trametinib (GSK1120212) compared with docetaxel in KRAS-mutant advanced non-small-cell lung cancer (NSCLC)†.

Authors:  G R Blumenschein; E F Smit; D Planchard; D-W Kim; J Cadranel; T De Pas; F Dunphy; K Udud; M-J Ahn; N H Hanna; J-H Kim; J Mazieres; S-W Kim; P Baas; E Rappold; S Redhu; A Puski; F S Wu; P A Jänne
Journal:  Ann Oncol       Date:  2015-02-26       Impact factor: 32.976
  5 in total
  8 in total

1.  Co-occurring genetic alterations predict distant metastasis and poor efficacy of first-line EGFR-TKIs in EGFR-mutant NSCLC.

Authors:  Li-Li Deng; Ge Gao; Hong-Bin Deng; Feng Wang; Zhi-Hui Wang; Yu Yang
Journal:  J Cancer Res Clin Oncol       Date:  2019-08-28       Impact factor: 4.553

2.  Combinatorial Inactivation of Tumor Suppressors Efficiently Initiates Lung Adenocarcinoma with Therapeutic Vulnerabilities.

Authors:  Maryam Yousefi; Gábor Boross; Carly Weiss; Christopher W Murray; Jess D Hebert; Hongchen Cai; Emily L Ashkin; Saswati Karmakar; Laura Andrejka; Leo Chen; Minwei Wang; Min K Tsai; Wen-Yang Lin; Chuan Li; Pegah Yakhchalian; Caterina I Colón; Su-Kit Chew; Pauline Chu; Charles Swanton; Christian A Kunder; Dmitri A Petrov; Monte M Winslow
Journal:  Cancer Res       Date:  2022-04-15       Impact factor: 13.312

Review 3.  Co-occurring genomic alterations in non-small-cell lung cancer biology and therapy.

Authors:  Ferdinandos Skoulidis; John V Heymach
Journal:  Nat Rev Cancer       Date:  2019-08-12       Impact factor: 60.716

4.  RASA1 inhibits the progression of renal cell carcinoma by decreasing the expression of miR-223-3p and promoting the expression of FBXW7.

Authors:  Rui-Li Zhang; Ainiwaer Aimudula; Jiang-Hong Dai; Yong-Xing Bao
Journal:  Biosci Rep       Date:  2020-07-31       Impact factor: 3.840

5.  Altered expression of ACOX2 in non-small cell lung cancer.

Authors:  Jane S Y Sui; Petra Martin; Anna Keogh; Pierre Murchan; Lisa Ryan; Siobhan Nicholson; Sinead Cuffe; Pilib Ó Broin; Stephen P Finn; Gerard J Fitzmaurice; Ronan Ryan; Vincent Young; Steven G Gray
Journal:  BMC Pulm Med       Date:  2022-08-23       Impact factor: 3.320

6.  Tumor Suppression of Ras GTPase-Activating Protein RASA5 through Antagonizing Ras Signaling Perturbation in Carcinomas.

Authors:  Lili Li; Yichao Fan; Xin Huang; Jie Luo; Lan Zhong; Xing-Sheng Shu; Li Lu; Tingxiu Xiang; Anthony T C Chan; Winnie Yeo; Ceshi Chen; Wai Yee Chan; Richard L Huganir; Qian Tao
Journal:  iScience       Date:  2019-10-08

Review 7.  Role of RASA1 in cancer: A review and update (Review).

Authors:  Yanhua Zhang; Yue Li; Quanyue Wang; Bo Su; Hui Xu; Yang Sun; Pei Sun; Rumeng Li; Xiaochun Peng; Jun Cai
Journal:  Oncol Rep       Date:  2020-10-13       Impact factor: 3.906

Review 8.  Tumorigenic bacteria in colorectal cancer: mechanisms and treatments.

Authors:  Sha Li; Jinyi Liu; Xiangjin Zheng; Liwen Ren; Yihui Yang; Wan Li; Weiqi Fu; Jinhua Wang; Guanhua Du
Journal:  Cancer Biol Med       Date:  2021-09-30       Impact factor: 4.248
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.